Thyroid C-cell tumor warning for applicable products
Important safety information
Know the risks before treatment.
Safety differs by condition, medicine, formulation, route, dose, health history, and other medicines. This overview does not replace the complete label, pharmacy instructions, or your treating licensed provider’s advice.
Urgent and crisis care
Quenva is not an emergency service.
For chest pain, stroke symptoms, severe allergic reaction, trouble breathing, an erection lasting more than four hours, or another medical emergency, call 911 or go to the nearest emergency department.
If you may act on thoughts of harming yourself or someone else, call 911. In the U.S., call or text 988 for the Suicide & Crisis Lifeline.GLP-1 and GLP-1/GIP risks are product-specific.
Share any personal or family history of medullary thyroid carcinoma or MEN 2, prior pancreatitis, gallbladder or kidney problems, severe stomach symptoms, diabetes medicines, eye complications, pregnancy or pregnancy plans, and all current medicines. Common effects may include nausea, vomiting, diarrhea, constipation, abdominal symptoms, fatigue, and injection-site reactions.
Pancreatitis and gallbladder problems
Dehydration-related kidney injury
Low blood sugar with certain diabetes medicines
Serious allergic reactions
Severe gastrointestinal problems
Compounded semaglutide and tirzepatide products are not FDA-approved and are not generic versions of approved drugs. FDA does not review compounded drugs for safety, effectiveness, or quality before marketing. Current legal availability depends on patient-specific need, pharmacy practice, federal law, and state law.
Hormone, vaginal, hair, and skin care require individualized review.
Share age, menstrual and pregnancy history, pregnancy potential or plans, anatomy, unexplained bleeding, cancer history, clotting or cardiovascular history, migraine, liver disease, current screening, and all medicines. Hormone risks differ by product, route, dose, anatomy, timing, and indication. Some vaginal symptoms require examination or testing rather than online treatment.
Unexplained vaginal bleeding
Cancer, clotting, stroke, and cardiovascular history
Pregnancy potential and reproductive goals
Need for progesterone with some systemic estrogen use
Product-specific blood-pressure, liver, and interaction risks
Hair and skin medicines with pregnancy precautions
Cardiovascular interactions and product status matter.
Sildenafil, tadalafil, and related erectile-dysfunction medicines must not be combined with nitrates and may be unsafe with riociguat or in some cardiovascular conditions. Seek emergency care for chest pain, sudden vision or hearing change, or an erection lasting more than four hours. Finasteride has pregnancy-exposure precautions and potential sexual or mood-related adverse effects. Oral minoxidil use for hair loss is off-label and can affect blood pressure and heart rate.
TRT requires diagnosis, laboratory confirmation, and monitoring.
Testosterone may suppress sperm production, increase blood pressure or hematocrit, worsen some sleep-apnea symptoms, and transfer from topical products to others. Review fertility plans, cardiovascular history, prostate and breast health, blood pressure, blood count, sleep apnea, and all current medicines. Testosterone products are Schedule III controlled substances and require product-specific prescribing and monitoring.
Compatible symptoms and repeat laboratory findings
Fertility and sperm-production effects
Blood pressure and hematocrit monitoring
Prostate, breast, and cardiovascular review
Topical transfer precautions
Sleep-apnea and in-person evaluation needs
Sedation, breathing symptoms, and next-day function matter.
Sleep medicines may cause sedation, next-day impairment, interactions, or complex behaviors. Possible sleep apnea, severe daytime impairment, unusual nighttime behaviors, pregnancy, substance withdrawal, or symptoms of another medical or psychiatric condition may require local testing, in-person evaluation, or specialist care.
Quenva’s planned online sleep pathway does not advertise benzodiazepines or controlled Z-drugs.
Outpatient telehealth is not crisis or emergency care.
Antidepressants carry warnings about increased suicidal thoughts and behaviors in children, adolescents, and young adults, especially early in treatment or after dose changes. Possible bipolar disorder, psychosis, eating disorder, substance withdrawal, immediate safety risk, or need for a higher level of support may require a different care setting.
Quenva does not advertise benzodiazepines, stimulants, or other controlled psychiatric medicines. Call or text 988 in the U.S. for crisis support and call 911 for immediate danger.
Approval belongs to the product and indication.
“Peptide” is not a wellness indication. Tesamorelin is FDA-approved for reducing excess abdominal fat in adults with HIV-associated lipodystrophy and is not indicated for general weight-loss management. Setmelanotide is approved only for qualifying rare genetic obesity disorders. Quenva does not present research-only peptides as approved human therapies.
Compounded drugs are not FDA-approved and are not generic versions of approved drugs. FDA does not review them for safety, effectiveness, or quality before marketing.
Read the medication-specific resources.
Wegovy® prescribing information Zepbound® prescribing information FDA compounded-drug promotion guidance FDA menopause medicine information FDA 2025 menopause hormone-therapy update FDA testosterone labeling update FDA antidepressant safety labeling FDA insomnia-medicine safety guidance EGRIFTA SV® / tesamorelin label FDA setmelanotide indication and safetyNeed immediate help?
Call 911 for an emergency. Call or text 988 in the U.S. for crisis support. For non-emergency treatment questions, message your licensed provider through the secure patient portal.